How Systemic Sclerosis Affects Healthcare Use and Complication Rates after Total Hip Arthroplasty

REFERENCES

1. 1.↵
   1. Chung L,
   2. Domsic RT,
   3. Lingala B,
   4. Alkassab F,
   5. Bolster M,
   6. Csuka ME,
   7. et al.

   Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res 2014;66:489–95.

   OpenUrlCrossRef
2. 2.↵
   1. Kennedy N,
   2. Walker J,
   3. Hakendorf P,
   4. Roberts-Thomson P

   . Improving life expectancy of patients with scleroderma: results from the South Australian scleroderma register. Intern Med J 2018;48:951–6.

   OpenUrl
3. 3.↵
   1. Cram P,
   2. Lu X,
   3. Kaboli PJ,
   4. Vaughan-Sarrazin MS,
   5. Cai X,
   6. Wolf BR,
   7. et al.

   Clinical characteristics and outcomes of medicare patients undergoing total hip arthroplasty, 1991–2008. JAMA 2011;305:1560–7.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Hofstede SN,
   2. Gademan MG,
   3. Vliet Vlieland TP,
   4. Nelissen RG,
   5. Marang-van de Mheen PJ

   . Preoperative predictors for outcomes after total hip replacement in patients with osteoarthritis: a systematic review. BMC Musculoskelet Disord 2016;17:212.

   OpenUrlPubMed
5. 5.↵
   Healthcare Cost and Utilization Project (HCUP). Overview of the National (Nationwide) Inpatient Sample (NIS). (Internet. Accessed February 25, 2020.) Available from: www.hcup-us.ahrq.gov/nisoverview.jsp
6. 6.↵
   1. Katz JN,
   2. Losina E,
   3. Barrett J,
   4. Phillips CB,
   5. Mahomed NN,
   6. Lew RA,
   7. et al.

   Association between hospital and surgeon procedure volume and outcomes of total hip replacement in the United States Medicare population. J Bone Joint Surg Am 2001;83:1622–9.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Singh JA,
   2. Ayub S

   . Accuracy of VA databases for diagnoses of knee replacement and hip replacement. Osteoarthritis Cartilage 2010;18:1639–42.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Bernatsky S,
   2. Linehan T,
   3. Hanly JG

   . The accuracy of administrative data diagnoses of systemic autoimmune rheumatic diseases. J Rheumatol 2011;38:1612–6.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Deyo RA,
   2. Cherkin DC,
   3. Ciol MA

   . Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–9.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Ram Poudel D,
    2. George M,
    3. Dhital R,
    4. Karmacharya P,
    5. Sandorfi N,
    6. Derk CT

    . Mortality, length of stay and cost of hospitalization among patients with systemic sclerosis: results from the National Inpatient Sample. Rheumatology 2018;57:1611–22.

    OpenUrl
11. 11.↵
    1. Casale R,
    2. Buonocore M,
    3. Matucci-Cerinic M

    . Systemic sclerosis (scleroderma): an integrated challenge in rehabilitation. Arch Phys Med Rehabil 1997;78:767–73.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Cinar FI,
    2. Unver V,
    3. Yilmaz S,
    4. Cinar M,
    5. Yilmaz F,
    6. Simsek I,
    7. et al.

    Living with scleroderma: patients’ perspectives, a phenomenological study. Rheumatol Int 2012;32:3573–9.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Antonioli CM,
    2. Bua G,
    3. Frige A,
    4. Prandini K,
    5. Radici S,
    6. Scarsi M,
    7. et al.

    An individualized rehabilitation program in patients with systemic sclerosis may improve quality of life and hand mobility. Clin Rheumatol 2009;28:159–65.

    OpenUrlPubMed
14. 14.↵
    1. Maddali-Bongi S,
    2. Del Rosso A

    . Systemic sclerosis: rehabilitation as a tool to cope with disability. Clin Exp Rheumatol 2016;34 Suppl 100:162–9.

    OpenUrl
15. 15.↵
    1. Maddali Bongi S,
    2. Del Rosso A,
    3. Galluccio F,
    4. Tai G,
    5. Sigismondi F,
    6. Passalacqua M,
    7. et al.

    Efficacy of a tailored rehabilitation program for systemic sclerosis. Clin Exp Rheumatol 2009;3 Suppl 54:44–50.

    OpenUrl
16. 16.↵
    1. Westerman MP,
    2. Martinez RC,
    3. Medsger TA Jr,
    4. Totten RS,
    5. Rodnan GP

    . Anemia and scleroderma: frequency, causes, and marrow findings. Arch Intern Med 1968;122:39–42.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Frayha RA,
    2. Shulman LE,
    3. Stevens MB

    . Hematological abnormalities in scleroderma. A study of 180 cases. Acta Haematol 1980;64:25–30.

    OpenUrlPubMed
18. 18.↵
    1. Melvin JS,
    2. Karthikeyan T,
    3. Cope R,
    4. Fehring TK

    . Early failures in total hip arthroplasty -- a changing paradigm. J Arthroplasty 2014;29:1285–8.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Pope JE

    . Musculoskeletal involvement in scleroderma. Rheum Dis Clin North Am 2003;29:391–408.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Amoda O,
    2. Ravat V,
    3. Datta S,
    4. Saroha B,
    5. Patel RS

    . Trends in demographics, hospitalization outcomes, comorbidities, and mortality risk among systemic sclerosis patients. Cureus 2018;10:e2628.

    OpenUrl